Efalizumab in the treatment of discoid lupus erythematosus

Archives of Dermatology

Volumn 143, Issue 7, 2007, Pages 873-877

  Usmani, Naila ^a   Goodfield, Mark ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG INDUCED HEADACHE; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LUPUS ERYTHEMATOSUS, DISCOID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447543051     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.7.873     Document Type: Article

References (16)

1. Goodfield MJD, Jones SK, Veale DJ. The "connective tissue diseases." In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rooks Textbook of Dermatology. Vol 3. 7th ed. Oxford, England: Blackwell Science; 2004:56.1-56.68.
2. Callen JP. Update on the management of cutaneous lupus erythematosus. Br J Dermatol. 2004;151(4):731-736.
3. Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum. 2002;46(5):1408-1409.
4. Aringer M, Graninger WF, Steiner G, Smolen J. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open label study. Arthritis Rheum. 2004;50(10):3161-3169.
5. Smith CH, Ansley A, Barker JN, et al; British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 [published correction appears in Br J Dermatol. 2005;153(5):1092]. Br J Dermatol. 2005;153(3):486-497.
6. El-Aziz K, Goodfield M. Quantifying disease activity and severity in patients with cutaneous lupus erythematosus [abstract]. J Eur Acad Dermatol Venereol. 2005; 19(suppl 2):128.
7. Wenzel J, Uerlich M, Worrenkamper E, Freutel S, Bieber T, Tuting T. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol. 2005;153(5):1011-1015.
8. Meijer C, Huysen V, Smeenk RT, Swaak AJ. Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus. 1993;2(6):359-365.
9. Shakoor N, Michalska M, Harris C, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359(9306):579-580.
10. Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rossa A. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol. 2005;11(1):47-49.
11. Bleumink GS, Borg EJ, Ramselaar CG, Ch Stricker BH. Etanercept induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford). 2001;40(11): 1317-1319.
12. Clayton TH, Ogden S, Goodfield M. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dermatol. 2006;54(5):892-895.
13. Goffe BS. Disseminated granuloma annulare resolved with the T-cell modulator efalizumab. Arch Dermatol. 2004;140(10):1287-1288.
14. Huber A, Gaffal E, Bieber T, Tuting T, Wenzel J. Treatment of recalcitrant dermatomyositis with efalizumab. Acta Derm Venereol. 2006;86(3):254-255.
15. Weinberg JM, Siegfried EC. Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch Dermatol. 2006;142(5):555-558.
16. Bentley DD, Graves JE, Smith DI, Heffernan MP. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2006;54(5)(suppl): S242-S243.